What is CDx Diagnostics?
CDx Diagnostics is dedicated to empowering physicians with innovative technology to prevent esophageal cancer. The company's proprietary diagnostic platform synthesizes computer imaging, artificial intelligence, molecular biology, and three-dimensional cytopathology to detect precancerous changes earlier and more reliably than previous methods. Their tests are designed for minimal practice time, cost-effectiveness, and broad reimbursement, addressing a critical gap in the current standard of care. Routine clinical use of CDx testing has already identified thousands of cancers and precancerous conditions, enabling timely and effective treatment.
How much funding has CDx Diagnostics raised?
CDx Diagnostics has raised a total of $13.5M across 2 funding rounds:
Unspecified
$11M
Series A
$2.5M
Unspecified (2019): $11M, investors not publicly disclosed
Series A (2025): $2.5M, investors not publicly disclosed
What's next for CDx Diagnostics?
The substantial enterprise-level funding indicates CDx Diagnostics is poised for significant scaling and further development of its groundbreaking diagnostic technology. This capital infusion will likely fuel expanded clinical trials, broader market penetration, and continued innovation in early cancer detection. The strategic investment suggests a strong belief from backers in the company's mission and its capacity to disrupt the diagnostic landscape, potentially leading to new partnerships and enhanced product offerings in the fight against esophageal cancer.
See full CDx Diagnostics company page
